IDXX vs. ZTS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at IDXX and ZTS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | IDXX | ZTS |
|---|---|---|
| Company Name | IDEXX Laboratories, Inc. | Zoetis Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Equipment & Supplies | Pharmaceuticals |
| Market Capitalization | 51.31 billion USD | 68.78 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | June 21, 1991 | February 1, 2013 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of IDXX and ZTS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | IDXX | ZTS |
|---|---|---|
| 5-Day Price Return | 0.73% | -0.31% |
| 13-Week Price Return | 27.04% | -4.19% |
| 26-Week Price Return | 42.21% | -0.93% |
| 52-Week Price Return | 30.43% | -14.81% |
| Month-to-Date Return | 20.03% | 6.45% |
| Year-to-Date Return | 55.13% | -4.75% |
| 10-Day Avg. Volume | 0.44M | 2.66M |
| 3-Month Avg. Volume | 0.65M | 3.12M |
| 3-Month Volatility | 60.25% | 22.63% |
| Beta | 1.59 | 0.92 |
Profitability
Return on Equity (TTM)
IDXX
64.42%
Health Care Equipment & Supplies Industry
- Max
- 34.53%
- Q3
- 19.38%
- Median
- 9.52%
- Q1
- 4.86%
- Min
- -7.58%
IDXX’s Return on Equity of 64.42% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
ZTS
53.21%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
ZTS’s Return on Equity of 53.21% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
IDXX
24.41%
Health Care Equipment & Supplies Industry
- Max
- 23.34%
- Q3
- 13.06%
- Median
- 9.53%
- Q1
- 5.96%
- Min
- -3.87%
IDXX’s Net Profit Margin of 24.41% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
ZTS
27.83%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
A Net Profit Margin of 27.83% places ZTS in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
IDXX
31.09%
Health Care Equipment & Supplies Industry
- Max
- 29.44%
- Q3
- 17.80%
- Median
- 13.95%
- Q1
- 8.73%
- Min
- -3.56%
IDXX’s Operating Profit Margin of 31.09% is exceptionally high, placing it well above the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.
ZTS
35.35%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
An Operating Profit Margin of 35.35% places ZTS in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | IDXX | ZTS |
|---|---|---|
| Return on Equity (TTM) | 64.42% | 53.21% |
| Return on Assets (TTM) | 29.89% | 18.27% |
| Net Profit Margin (TTM) | 24.41% | 27.83% |
| Operating Profit Margin (TTM) | 31.09% | 35.35% |
| Gross Profit Margin (TTM) | 61.54% | 71.50% |
Financial Strength
Current Ratio (MRQ)
IDXX
1.11
Health Care Equipment & Supplies Industry
- Max
- 4.90
- Q3
- 3.05
- Median
- 2.14
- Q1
- 1.49
- Min
- 0.86
IDXX’s Current Ratio of 1.11 falls into the lower quartile for the Health Care Equipment & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
ZTS
1.76
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
ZTS’s Current Ratio of 1.76 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
IDXX
0.76
Health Care Equipment & Supplies Industry
- Max
- 1.49
- Q3
- 0.71
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
IDXX’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 0.76. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
ZTS
1.32
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
ZTS’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 1.32. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
IDXX
49.24
Health Care Equipment & Supplies Industry
- Max
- 58.29
- Q3
- 25.56
- Median
- 9.06
- Q1
- 3.60
- Min
- -28.92
IDXX’s Interest Coverage Ratio of 49.24 is in the upper quartile for the Health Care Equipment & Supplies industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
ZTS
15.44
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
ZTS’s Interest Coverage Ratio of 15.44 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | IDXX | ZTS |
|---|---|---|
| Current Ratio (MRQ) | 1.11 | 1.76 |
| Quick Ratio (MRQ) | 0.75 | 1.04 |
| Debt-to-Equity Ratio (MRQ) | 0.76 | 1.32 |
| Interest Coverage Ratio (TTM) | 49.24 | 15.44 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
IDXX
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.05%
- Q3
- 1.76%
- Median
- 0.71%
- Q1
- 0.00%
- Min
- 0.00%
IDXX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
ZTS
1.24%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
ZTS’s Dividend Yield of 1.24% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
IDXX
0.00%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 72.47%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
IDXX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
ZTS
32.08%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
ZTS’s Dividend Payout Ratio of 32.08% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | IDXX | ZTS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 1.24% |
| Dividend Payout Ratio (TTM) | 0.00% | 32.08% |
Valuation
Price-to-Earnings Ratio (TTM)
IDXX
51.66
Health Care Equipment & Supplies Industry
- Max
- 73.48
- Q3
- 51.69
- Median
- 34.31
- Q1
- 25.74
- Min
- 11.47
IDXX’s P/E Ratio of 51.66 is within the middle range for the Health Care Equipment & Supplies industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
ZTS
25.93
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
ZTS’s P/E Ratio of 25.93 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
IDXX
12.61
Health Care Equipment & Supplies Industry
- Max
- 9.53
- Q3
- 5.26
- Median
- 3.39
- Q1
- 2.13
- Min
- 0.00
With a P/S Ratio of 12.61, IDXX trades at a valuation that eclipses even the highest in the Health Care Equipment & Supplies industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
ZTS
7.22
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
ZTS’s P/S Ratio of 7.22 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
IDXX
29.57
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 5.98
- Median
- 3.48
- Q1
- 2.43
- Min
- 0.69
At 29.57, IDXX’s P/B Ratio is at an extreme premium to the Health Care Equipment & Supplies industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
ZTS
13.95
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
At 13.95, ZTS’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | IDXX | ZTS |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 51.66 | 25.93 |
| Price-to-Sales Ratio (TTM) | 12.61 | 7.22 |
| Price-to-Book Ratio (MRQ) | 29.57 | 13.95 |
| Price-to-Free Cash Flow Ratio (TTM) | 65.76 | 30.52 |